Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,814.56 +94.06 (+0.24%) Hang Seng
17,941.78 -170.82 (-0.94%) FTSE 100
8,146.86 -16.81 (-0.21%) Bitcoin USD
66,469.64 +406.45 (+0.62%) CMC Crypto 200
1,382.40 -35.47 (-2.50%)
ARWR Jun 2024 35.000 call
| Previous close | 0.1100 |
| Open | 0.1000 |
| Bid | 0.0000 |
| Ask | 0.2500 |
| Strike | 35.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.1000 - 0.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 715 |
BenzingaWhy Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday?
On Monday, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) released topline results from the Phase 3 PALISADE study of plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS). FCS is a rare metabolic disease that prevents the body from digesting fats. Related: What Arrowhead Pharmaceutical’s Interim Data Reveals About A RNAi Therapeutic For Rare Cholesterol Disorder The study met the primary endpoint of lowering triglycerides and all key sec
Business WireArrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
PASADENA, Calif., June 03, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), a severe genetic disease with significant unmet need and no FDA approved therapies. PALISADE successfully met the primary endpoint of lowering triglycerides and met all key secondary endpoints, including reducing t
Business WireArrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
PASADENA, Calif., May 31, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
